What is HC Wainwright’s Estimate for CRVS FY2025 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Stock analysts at HC Wainwright increased their FY2025 EPS estimates for Corvus Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 26th. HC Wainwright analyst S. Lee now expects that the company will earn ($0.43) per share for the year, up from their previous forecast of ($0.44). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2027 earnings at ($0.32) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06).

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price target (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.67.

Corvus Pharmaceuticals Stock Performance

NASDAQ:CRVS opened at $3.38 on Friday. The stock has a 50-day simple moving average of $4.61 and a 200 day simple moving average of $6.05. Corvus Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $10.00. The company has a market cap of $217.19 million, a PE ratio of -3.63 and a beta of 0.91.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Avity Investment Management Inc. raised its stake in shares of Corvus Pharmaceuticals by 7.6% during the 4th quarter. Avity Investment Management Inc. now owns 29,680 shares of the company’s stock worth $159,000 after purchasing an additional 2,100 shares in the last quarter. Geode Capital Management LLC increased its holdings in Corvus Pharmaceuticals by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 566,863 shares of the company’s stock worth $3,034,000 after buying an additional 3,854 shares during the last quarter. Renaissance Technologies LLC raised its position in Corvus Pharmaceuticals by 1.1% during the fourth quarter. Renaissance Technologies LLC now owns 390,688 shares of the company’s stock worth $2,090,000 after acquiring an additional 4,100 shares in the last quarter. Nwam LLC lifted its stake in Corvus Pharmaceuticals by 54.2% in the fourth quarter. Nwam LLC now owns 15,500 shares of the company’s stock valued at $83,000 after acquiring an additional 5,450 shares during the last quarter. Finally, Virtus ETF Advisers LLC bought a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at about $47,000. 46.64% of the stock is owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.